Publisher
Springer Science and Business Media LLC
Reference36 articles.
1. Ponte JF, Ab O, Lanieri L, et al. Mirvetuximab soravtansine (IMGN853), a folate receptor alpha-targeting antibody-drug conjugate, potentiates the activity of standard of care therapeutics in Ovarian cancer models. Neoplasia. 2016;18(12):775–84.
2. Martin LP, Konner JA, Moore KN, et al. Characterization of folate receptor alpha (FR alpha) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: a phase I expansion study of the FR alpha-targeting antibody-drug conjugate mirvetuximab soravtansine. Gynecol Oncol. 2017;147(2):402–7.
3. Food & Drug Administration. FDA grants accelerated approval to mirvetuximab soravtansine-gynx for FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or peritoneal cancer [media release]. 14 Nov 2022. https://www.fda.gov/
4. ImmunoGen. ElahereTM (mirvetuximab soravtansine-gynx) injection, for intravenous use. 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761310s000lbl.pdf. Accessed 28 Nov 2022.
5. Yam C, Rauch GM, Rahman T, et al. A phase II study of mirvetuximab soravtansine in triple-negative breast cancer. Invest New Drugs. 2021;39(2):509–15.
Cited by
46 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献